Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 1/20 | 0.61 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.51 |
| ▸ | HTR2A | P28223 | 1/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.43 |
| ▸ | NQO2 | P16083 | 1/20 | 0.40 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.40 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.40 |
| ▸ | HTR6 | P50406 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL32669227 | 0.87 | HTR1A (0.46) | HTR1AHRH3HTR2ASIGMAR1KCNH2 | |
| SCHEMBL16286333 | 0.82 | HRH3 (0.45) | HTR1AHRH3HTR2ASIGMAR1KCNH2 | |
| SCHEMBL1163148 | 0.80 | HTR1A (0.52) | HTR1AHRH3HTR2ASIGMAR1KCNH2 | |
| SCHEMBL29633073 | 0.76 | HTR1A (1.00) | HTR1AHRH3HTR2AHTR6 | |
| SCHEMBL20970863 | 0.76 | HTR1A (1.00) | HTR1AHRH3HTR2AHTR6 | |
| SCHEMBL32669417 | 0.75 | HTR1A (0.98) | HTR1AHRH3HTR2AHTR6 | |
| SCHEMBL1163191 | 0.75 | HRH3 (0.37) | HTR1AHRH3HTR2AHTR6ALDH1A1 | |
| SCHEMBL1163641 | 0.72 | SLC6A4 (0.40) | HTR1AHRH3HTR2ASIGMAR1KCNH2 | |
| SCHEMBL32669268 | 0.71 | ADRB2 (0.67) | HRH3HTR2ANQO2MTNR1AMTNR1B | |
| SCHEMBL1163605 | 0.69 | ALDH1A1 (0.41) | HTR1AHRH3SIGMAR1KCNH2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260034119-A1 | 5-METHOXY-N,N-DIMETHYLTRYPTAMINE ANALOGS, THEIR SYNTHESIS, AND METHODS FOR TREATMENT OF NEUROLOGICAL, PSYCHIATRIC, AND SUBSTANCE USE DISORDERS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2026-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260034119-A1 | 5-METHOXY-N,N-DIMETHYLTRYPTAMINE ANALOGS, THEIR SYNTHESIS, AND METHODS FOR TREATMENT OF NEUROLOGICAL, PSYCHIATRIC, AND SUBSTANCE USE DISORDERS | HTR4, OPRM1, HTR7 | HTR1A 4/4885HRH3 117/4885HTR2A 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.